Vyome Holdings, Inc. (NASDAQ:HIND) Sees Large Increase in Short Interest

Vyome Holdings, Inc. (NASDAQ:HIND) saw a large increase in short interest in December. As of December 15th, there was short interest totaling 76,872 shares, an increase of 272.0% from the November 30th total of 20,666 shares. Based on an average daily trading volume, of 93,344 shares, the days-to-cover ratio is presently 0.8 days. Currently, 2.0% of the company’s stock are short sold. Currently, 2.0% of the company’s stock are short sold. Based on an average daily trading volume, of 93,344 shares, the days-to-cover ratio is presently 0.8 days.

Vyome Stock Performance

Shares of HIND traded up $0.13 during trading hours on Thursday, hitting $3.76. 5,776 shares of the company were exchanged, compared to its average volume of 63,751. The company has a market capitalization of $21.21 million, a P/E ratio of -0.03 and a beta of 1.21. The company’s 50 day simple moving average is $5.04. Vyome has a 52 week low of $3.57 and a 52 week high of $519.00.

Vyome (NASDAQ:HIND) last posted its earnings results on Friday, November 14th. The company reported ($3.12) earnings per share for the quarter. The company had revenue of $0.04 million during the quarter. Vyome had a negative return on equity of 423.39% and a negative net margin of 270.58%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Citigroup upgraded Vyome to a “buy” rating in a report on Thursday, October 2nd. Weiss Ratings reaffirmed a “sell (e-)” rating on shares of Vyome in a research note on Monday. Maxim Group reiterated a “buy” rating and set a $15.00 price target on shares of Vyome in a report on Thursday, October 2nd. Finally, Wall Street Zen upgraded Vyome from a “sell” rating to a “hold” rating in a report on Thursday, October 9th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $15.00.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.